By Kashish Tandon (Reuters) -Shares of India's Glenmark Pharmaceuticals jumped 10% to a record high on Friday, a day after ...

Glenmark Pharmaceuticals Ltd.’s licensing pact with AbbVie Inc. for its blood cancer drug is boosting optimism over Indian ...

With a $2-billion cancer drug deal in its pocket, Glenmark’s licensing agreement with AbbVie not only unlocks a potential ...

India's Glenmark Pharmaceuticals said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie have ...

With a robust trading session and positive momentum, Glenmark is showing very bullish sentiment as per Moneycontrol analysis.

The deal also entails $1.23 billion in milestone payments. While Glenmark unit IGI will retain rights for India and emerging ...

Glenmark Pharmaceuticals' shares surged 10% to an all-time high of ₹2,094 following the announcement of an exclusive ...

We’ve gone through blood, sweat, and tears to get here. This validates everything we’ve built,' Saldanha says as Glenmark ...

HSBC and Axis Capital are more bullish on its transformative impact and future growth prospects for Glenmark, while Nuvama ...

Glenmark shares hit record high after $2 billion AbbVie deal for cancer drug ISB 2001; analysts see it as a major biotech ...

Glenmark Pharma surged 14% after its subsidiary signed a $700 million licensing deal with AbbVie for its experimental cancer ...